Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

Trial Profile

Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Albiglutide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 02 Jun 2020 Results from DEFEND-1 (n=53) NCT02284009 finding whether GLP-1 receptor agonist lessen the loss of beta cell function after T1D diagnosis, published in the Journal of Clinical Endocrinology and Metabolism
    • 27 Mar 2020 Primary endpoint (Mean change from baseline in stimulated (from Mixed meal tolerance test [MMTT]) plasma C-peptide area under the curve (AUC) at Week 52) has not been met published in the Journal of Clinical Endocrinology and Metabolism
    • 27 Mar 2020 Results assessing efficacy and safety of once-weekly albiglutide 30mg (up-titration to 50mg at week 6) versus placebo together with insulin in patients with new-onset type 1 diabetes and residual insulin production published in the Journal of Clinical Endocrinology and Metabolism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top